Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0008325 (cholecystitis)
 3,686 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case of unusual cholecystitis that developed on completion of interleukin-2 and lymphokine-activated killer cell therapy is described. A 62-year-old man was treated with interleukin-2 and lymphokine-activated killer cells for disseminated renal cell carcinoma. During the course of the immunotherapy, his serum alkaline phosphatase level increased, as did the peripheral eosinophil count (0.31). Subsequently, clinical and radiologic evidence of acute cholecystitis was noted. The removed gallbladder showed acalculus cholecystitis with extensive diffuse infiltrates of numerous eosinophils and T lymphocytes, but sparse polymorphonuclear leukocytes. The authors name this unusual cholecystitis acalculus lymphoeosinophilic cholecystitis and believe it to be associated with interleukin-2 and lymphokine-activated killer cell therapy. The pathogenic relationship is discussed.
 ...
PMID:Acalculus lymphoeosinophilic cholecystitis associated with interleukin-2 and lymphokine-activated killer cell therapy. 222 49

We report a case of interleukin-2 (IL-2) induced cholangiopathy diagnosed with the aid of hepatobiliary scintigraphy. Patient was a 32 years old, male with history of metastatic melanoma. Computed tomography (CT) upon admission demonstrated worsening of patient's metastatic lung disease with a normal appearance of the gallbladder. The patient was started on high dose IL-2 treatment for regression of his disease. Four days after IL-2 treatment was begun, the patient developed severe right upper quadrant pain and elevated liver function tests. A right upper quadrant ultrasound and surgical consultation were requested. Sonographic findings demonstrated diffuse gallbladder wall thickening, mural edema, a positive sonographic Murphy's sign, but no gallstones. The preliminary working diagnosis was acalculous cholecystitis versus IL-2 induced cholangiopathy. To clarify between these two entities, a hepatobiliary scan was obtained that demonstrated filling of the gallbladder with prompt biliary-to-bowel transit and normal liver function. In this case, the clinical presentation and history of recent IL-2 treatment were suggestive of IL-2 cholangiopathy, though the patient's co-morbidities and in-patient status raised concern for acalculous cholecystitis. Given the marked differences in treatment, hepatobiliary imaging was requested and found to be normal, making acalculous cholecystitis very unlikely. In conclusion, we believe this is the first case in which hepatobiliary scintigraphy was used to aid in the diagnosis of IL-2 induced cholangiopathy.
 ...
PMID:Novel use of hepatobiliary scintigraphy for the diagnosis of interleukin-2 cholangiopathy. 2080 91

The results of application of systemic cytokinotherapy and splenopid in patients, operated on for an acute calculous cholecystitis, are presented. While in patients of a control group the conventional basic therapy was conducted, to the patients of the main group the systemic cytokinotherapy and splenopid were conducted preoperatively and postoperatively on background of basic therapy during 3-10 days at average. In both groups preoperatively the reduction of interleukin-2 (IL-2) and gamma-interferon (IFNgamma) content were observed, as well as raising of the blood level of the tumor necrosis factor-alpha (TNF-alpha), IL-6 and IL-10. In the patients of a control group a tendency towards the studied indices normalisation was noted postoperatively, and in the patients of the main group the elimination of the organism cytokine state dysbalance was achieved. While doing comparative analysis of ratio of TNF-alpha/IL-10 and IL-2/IL-10 in the blood serum in the main group there was established, that up to the observation period end the both indices were close to the norm.
 ...
PMID:[The cytokine profile in the patients with acute calculous cholecystitis and correction of its disorders]. 2388 11